Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.

Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O'Quinn R, Savona MR, Slosky D, Smith A, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D.

J Clin Oncol. 2019 Jun 12:JCO1900231. doi: 10.1200/JCO.19.00231. [Epub ahead of print]

PMID:
31188726
2.

Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.

Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S.

Clin Lymphoma Myeloma Leuk. 2019 Feb 20. pii: S2152-2650(18)31257-6. doi: 10.1016/j.clml.2019.02.004. [Epub ahead of print] Review.

PMID:
31023594
3.

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC.

J Clin Invest. 2019 Mar 21;130:2210-2221. doi: 10.1172/JCI126397.

4.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2019 Feb 21;4(4). pii: 127684. doi: 10.1172/jci.insight.127684. eCollection 2019 Feb 21. No abstract available.

5.

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.

Zhou N, Gutierrez-Uzquiza A, Zheng XY, Chang R, Vogl DT, Garfall AL, Bernabei L, Saraf A, Florens L, Washburn MP, Illendula A, Bushweller JH, Busino L.

Leukemia. 2019 Feb 13. doi: 10.1038/s41375-019-0403-2. [Epub ahead of print]

PMID:
30760870
6.

Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications.

Susanibar Adaniya SP, Cohen AD, Garfall AL.

Am J Hematol. 2019 May;94(S1):S28-S33. doi: 10.1002/ajh.25428. Epub 2019 Feb 25. Review.

PMID:
30730071
7.

Acute Liver Failure Associated With Pomalidomide Therapy for Multiple Myeloma.

Reed-Guy L, Hoteit MA, Garfall AL.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e337-e338. doi: 10.1016/j.clml.2018.05.012. Epub 2018 May 26. No abstract available.

PMID:
29907543
8.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2018 Apr 19;3(8). pii: 120505. doi: 10.1172/jci.insight.120505. eCollection 2018 Apr 19. Erratum in: JCI Insight. 2019 Feb 21;4(4):.

9.

Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.

Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, O'Quinn R, Cohen AD, Stadtmauer EA, Ky B, Weiss BM.

JAMA Oncol. 2018 Mar 8;4(3):e174519. doi: 10.1001/jamaoncol.2017.4519. Epub 2018 Mar 8.

10.

Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.

Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A, Nefedova Y, Lin C, Partlova S, Garfall A, Vogl DT, Xu X, Knight SC, Malietzis G, Lee GH, Eruslanov E, Albelda SM, Wang X, Mehta JL, Bewtra M, Rustgi A, Hockstein N, Witt R, Masters G, Nam B, Smirnov D, Sepulveda MA, Gabrilovich DI.

Sci Immunol. 2016 Aug;1(2). pii: aaf8943. doi: 10.1126/sciimmunol.aaf8943. Epub 2016 Aug 5.

11.

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts.

Brunstein CG, Cutler CS, DeFor TE, Kim H, Bejanyan N, Garfall A, Verneris MR, Chen YB, Warlick ED, Spitzer T, Miller JS, Antin JH, Weisdorf DJ, Soiffer R, Wagner JE, Ballen KK.

Biol Blood Marrow Transplant. 2017 Jan;23(1):126-133. doi: 10.1016/j.bbmt.2016.10.018. Epub 2016 Oct 29.

12.

Cellular and vaccine immunotherapy for multiple myeloma.

Garfall AL, Stadtmauer EA.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):521-527. Review.

13.

Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer.

Singhal S, Bhojnagarwala PS, O'Brien S, Moon EK, Garfall AL, Rao AS, Quatromoni JG, Stephen TL, Litzky L, Deshpande C, Feldman MD, Hancock WW, Conejo-Garcia JR, Albelda SM, Eruslanov EB.

Cancer Cell. 2016 Jul 11;30(1):120-135. doi: 10.1016/j.ccell.2016.06.001. Epub 2016 Jun 30.

14.

The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.

Nagle SJ, Garfall AL, Stadtmauer EA.

Cancer J. 2016 Jan-Feb;22(1):27-33. doi: 10.1097/PPO.0000000000000166. Review.

15.

Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer.

Akkari L, Gocheva V, Quick ML, Kester JC, Spencer AK, Garfall AL, Bowman RL, Joyce JA.

Genes Dev. 2016 Jan 15;30(2):220-32. doi: 10.1101/gad.270439.115.

16.

Chimeric Antigen Receptor T Cells in Myeloma.

Garfall AL, Stadtmauer EA, June CH.

N Engl J Med. 2016 Jan 14;374(2):194. doi: 10.1056/NEJMc1512760. No abstract available.

PMID:
26760100
17.

Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study.

Huntington SF, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, Doshi JA, Stadtmauer EA.

Lancet Haematol. 2015 Oct;2(10):e408-16. doi: 10.1016/S2352-3026(15)00151-9. Epub 2015 Sep 17.

PMID:
26686042
18.

Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.

Ramachandran IR, Condamine T, Lin C, Herlihy SE, Garfall A, Vogl DT, Gabrilovich DI, Nefedova Y.

Cancer Lett. 2016 Feb 1;371(1):117-24. doi: 10.1016/j.canlet.2015.10.040. Epub 2015 Nov 27.

19.

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.

Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, Stadtmauer EA.

N Engl J Med. 2015 Sep 10;373(11):1040-7. doi: 10.1056/NEJMoa1504542.

20.

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.

Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A.

Bone Marrow Transplant. 2015 Dec;50(12):1513-8. doi: 10.1038/bmt.2015.190. Epub 2015 Aug 24.

21.

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH.

Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20.

22.

Classifying ultra-high risk smoldering myeloma.

Waxman AJ, Mick R, Garfall AL, Cohen A, Vogl DT, Stadtmauer EA, Weiss BM.

Leukemia. 2015 Mar;29(3):751-3. doi: 10.1038/leu.2014.313. Epub 2014 Nov 5. No abstract available.

PMID:
25371175
23.

Association between mobilization regimen and PFS after auto-SCT for multiple myeloma.

Garfall AL, Dougherty AL, Vogl DT, Weiss BM, Cohen AD, Mick R, O'Doherty U, Stadtmauer EA.

Bone Marrow Transplant. 2014 Nov;49(11):1439-41. doi: 10.1038/bmt.2014.153. Epub 2014 Jul 21. No abstract available.

24.

Trials and Tribulations with VH Replacement.

Meng W, Jayaraman S, Zhang B, Schwartz GW, Daber RD, Hershberg U, Garfall AL, Carlson CS, Luning Prak ET.

Front Immunol. 2014 Jan 30;5:10. doi: 10.3389/fimmu.2014.00010. eCollection 2014. Review.

25.

Immunotherapy with chimeric antigen receptors for multiple myeloma.

Garfall AL, Fraietta JA, Maus MV.

Discov Med. 2014 Jan;17(91):37-46. Review.

26.

Cellular immunotherapy for plasma cell myeloma.

Garfall AL, Vogl DT, Weiss BM, Stadtmauer EA.

Bone Marrow Transplant. 2013 Nov;48(11):1377-86. doi: 10.1038/bmt.2013.54. Epub 2013 May 6. Review.

PMID:
23645169
27.

KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation.

Garfall A, Kim HT, Sun L, Ho VT, Armand P, Koreth J, Alyea EP, Soiffer RJ, Antin JH, Ritz J, Cutler C.

Bone Marrow Transplant. 2013 Jul;48(7):1000-2. doi: 10.1038/bmt.2012.272. Epub 2013 Jan 14. No abstract available.

PMID:
23318536
28.

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.

Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA.

Genes Dev. 2011 Dec 1;25(23):2465-79. doi: 10.1101/gad.180331.111.

29.

IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion.

Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, Berman T, Joyce JA.

Genes Dev. 2010 Feb 1;24(3):241-55. doi: 10.1101/gad.1874010. Epub 2010 Jan 15.

30.

Promoting professionalism through an online professional development portfolio: successes, joys, and frustrations.

Kalet AL, Sanger J, Chase J, Keller A, Schwartz MD, Fishman ML, Garfall AL, Kitay A.

Acad Med. 2007 Nov;82(11):1065-72.

PMID:
17971693
31.
32.

Reflections on the role of the professionalism curriculum in medical school.

Fishman M, Garfall A, Thomas JM.

Virtual Mentor. 2007 Apr 1;9(4):259-61. doi: 10.1001/virtualmentor.2007.9.4.fred1-0704. No abstract available.

PMID:
23217965

Supplemental Content

Loading ...
Support Center